Efpeglenatide
Sources
registry, as of 2021-10-15Stale
https://clinicaltrials.gov/study/NCT03770728
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea. Overall status TERMINATED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 312. Conditions Type 2 Diabetes Mellitus. Primary Objective: To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin alone or in combination with sul
ClinicalTrials.gov NCT03770728 protocol and results modules
registry, as of 2021-11-01Stale
https://clinicaltrials.gov/study/NCT03684642
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin. Overall status TERMINATED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 908. Conditions Type 2 Diabetes Mellitus. Primary Objective: To demonstrate the non-inferiority of once weekly injection of efpeglenatide in comparison to once weekly injection of dulaglutide on glycated hemoglobin (HbA1c) change in participants with Type 2 diabetes mellitus (T2DM) inadequately controlled with metformin
ClinicalTrials.gov NCT03684642 protocol and results modules
registry, as of 2022-01-18Stale
https://clinicaltrials.gov/study/NCT03353350
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise. Overall status COMPLETED. Phases PHASE3. Lead sponsor Hanmi Pharmaceutical Company Limited. Enrollment 406. Conditions Type 2 Diabetes Mellitus. Primary Objective: To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with T2DM (Type 2 Diabetes Mellitus) inadequately controlled with diet and exercise. Secondary Objectives:
ClinicalTrials.gov NCT03353350 protocol and results modules
registry, as of 2021-12-02Stale
https://clinicaltrials.gov/study/NCT03713684
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s). Overall status TERMINATED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 370. Conditions Type 2 Diabetes Mellitus. Primary Objective: To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with type 2 diabetes mellitus (T2DM) inadequately controlled with basal insulin alone or in combination with
ClinicalTrials.gov NCT03713684 protocol and results modules
registry, as of 2021-10-15Stale
https://clinicaltrials.gov/study/NCT03496298
Effect of Efpeglenatide on Cardiovascular Outcomes. Overall status TERMINATED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 4076. Conditions Type 2 Diabetes Mellitus. Primary Objective: To demonstrate that efpeglenatide 4 and 6 mg was noninferior to placebo on 3-point major adverse cardiac events (MACE) in Type 2 diabetes mellitus (T2DM) participants at high cardiovascular (CV) risk. Secondary Objectives: To demonstrate that efpeglenatide 4
ClinicalTrials.gov NCT03496298 protocol and results modules